ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: 84% Of Micromet Shares Have Been Tendered

DOW JONES NEWSWIRES Amgen Inc. (AMGN) said nearly 84% of the shares of biotechnology company Micromet Inc. (MITI) have been tendered to its $1.16 billion takeover offer, meeting all the conditions for the acquisition to close. As of the offering's expiration Thursday, about 80 million Micromet shares had been tendered and not withdrawn. An added 3.15 million shares have been tendered by guaranteed delivery. A subsequent offering period is scheduled to expire at 12:00 a.m. EST, at the end of March 6. Amgen launched its bid to acquire Micromet in January with an aim to strengthen Amgen's cancer-drug research pipeline. A Delaware judge declined to block Amgen's purchase of Micromet, the Associated Press reported Thursday. A group of Micromet shareholders had argued that Micromet didn't try hard enough to get a better offer, and sought a preliminary injunction. The judge found that the shareholders didn't show a reasonable likelihood that they would successfully prove their claims, the AP reported. Amgen shares closed at $67.59 Thursday and were inactive premarket. The stock is up 32% in the past 12 months. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
09/03/201507:14:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S...
09/03/201505:24:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/03/201504:00:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/02/201519:47:24Statement of Changes in Beneficial Ownership (4)
09/02/201516:30:00Novartis Closer to Selling Copy of Amgen's Neupogen
09/02/201516:22:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen...
09/02/201516:16:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen
09/02/201516:01:00Amgen Submits Marketing Authorization Application For Novel Intravenous...
09/02/201502:00:00Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs
09/01/201516:30:00Amgen Enters Into Neuroscience Collaboration With Novartis For...
09/01/201516:01:00Amgen And UCB Announce Positive Top-Line Results From Open-Label...
09/01/201512:40:00Amgen Finds Data Falsified in Grizzly Bear Study
09/01/201509:58:00Valeant Strikes Psoriasis-Drug Pact With AstraZeneca -- Update
09/01/201504:10:00Valeant Strikes Psoriasis-Drug Pact With AstraZeneca
09/01/201503:42:00Valeant Strikes Psoriasis-Drug Pact With AstraZeneca
08/27/201520:00:00FDA Approves Amgen's Cholesterol-Lowering Drug Repatha -- Update
08/27/201519:20:00FDA Approves New Amgen Cholesterol Drug
08/27/201518:40:00FDA Approves Amgen's Repatha Cholesterol Drug
08/27/201517:50:00FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™...
08/25/201509:45:00U.S. Hot Stocks: Hot Stocks to Watch

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad